Serum nitric oxide metabolites in subjects with metabolic syndrome

Our aim was to evaluate lipid peroxidation, expressed as thiobarbituric acid-reactive substances (TBARS), nitric oxide metabolites (nitrite + nitrate) expressed asNOx, and TBARS/NOxratio in a group of subjects with metabolic syndrome (MS). In this regard we enrolled 106 subjects with MS defined according to the IDF criteria, subsequently subdivided into diabetic (DMS) and nondiabetic (NDMS) and also into subjects with a low triglycerides/HDL-cholesterol (TG/HDL-C) index or with a high TG/HDL-C index. In the entire group and in the four subgroups of MS subjects we found an increase in TBARS andNOxlevels and a decrease in TBARS/NOxratio in comparison with normal controls. Regarding all these parameters no statistical difference between DMS and NDMS was evident, but a significant increase inNOxwas present in subjects with a high TG/HDL-C index in comparison with those with a low index. In MS subjects we also found a negative correlation between TBARS/NOxratio and TG/HDL-C index. Considering the hyperactivity of the inducible NO synthase in MS, these data confirm the altered redox and inflammatory status that characterizes the MS and suggest a link between lipid peroxidation, inflammation, and insulin resistance, evaluated as TG/HDL-C index.

Download Full-text

Serum Nitric Oxide Metabolites and the Incidence of Metabolic Syndrome and Its Phenotypes: A Population-Based Prospective Study

Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders ◽

10.1016/b978-0-12-816545-4.00015-3 ◽

2019 ◽

pp. 309-310

Author(s):

Zahra Bahadoran ◽

Parvin Mirmiran ◽

Fereidoun Azizi ◽

Asghar Ghasemi

Keyword(s):

Nitric Oxide ◽

Metabolic Syndrome ◽

Prospective Study ◽

Population Based ◽

Nitric Oxide Metabolites

Download Full-text

High serum nitric oxide metabolites and incident metabolic syndrome

Scandinavian Journal of Clinical and Laboratory Investigation ◽

10.3109/00365513.2012.701322 ◽

2012 ◽

Vol 72 (7) ◽

pp. 523-530 ◽

Cited By ~ 13

Author(s):

Asghar Ghasemi ◽

Saleh Zahediasl ◽

Fereidoun Azizi

Keyword(s):

Nitric Oxide ◽

Metabolic Syndrome ◽

High Serum ◽

Nitric Oxide Metabolites

Download Full-text

Abstract 169: Stable Nitric Oxide Metabolites Levels and Their Relation to the Metabolic Syndrome Components in Essential Hypertension

Hypertension ◽

10.1161/hyp.62.suppl_1.a169 ◽

2013 ◽

Vol 62 (suppl_1) ◽

Author(s):

Natalia Murashko ◽

Valery Podzolkov ◽

Anna Bragina

Keyword(s):

Nitric Oxide ◽

Metabolic Syndrome ◽

Essential Hypertension ◽

Visceral Obesity ◽

High Plasma ◽

Glucose Levels ◽

The Metabolic Syndrome ◽

Blood Glucose Levels ◽

Nitric Oxide Metabolites ◽

Plasma Leptin

Objective: To investigate levels of the stable nitric oxide metabolites (NOx) in relation to components of the metabolic syndrome (MS) in essential hypertension (EH) Methods: We examined 124 untreated patients with EH (mean age 51.4 ± 6.5 years, mean hypertension duration 8,5±7,6 years) and 25 healthy volunteers with comparable age (47.2 ± 7.8 years, p>0,05). Plasma leptin levels were measured by radioimmunoassay, plasma NOx - by spectrophotometry. Results were processed with Statistica 6.0 software. Results: Visceral obesity had 64% of hypertensive patients, dyslipidemia - 80.6%, hyperglycemia - 41,6%, MS - 24%. In 32% the MS diagnosis was based on the presence of two additional criteria, in 68% - on three. NOx levels were significantly higher in hypertensives (43,18±21, μmol/l) than in controls (28.3 ± 9.6 μmol/l) ( p = 0.01). In patients with hyperglycemia NOx concentration was higher (46,5 ± 23,9 μmol/l) than in those without it (38,6±18, μmol/l)(p<0,05). NOx levels correlated with blood glucose levels (r=0,32, p<0,05). NOx concentration did not differ between hypertensives with or without dyslipidemia (43,2±22,2 and 42,05±21,1 μmol/l, accordingly p>0,05). Nonobese hypertensives had lower NOx concentration than obese hypertensives (38,8±17,9 and 48,5±24,7 μmol/l, p<0,05). NOx levels correlated with the presence (r=-0,44, p<0,05) and degree of obesity (r=-0,3, p<0,05). NOx levels were lower in patients with MS (31,6±11,3 and 47,05±20,7 μmol/l, p<0,05). NOx levels decreased with the increase of additional MS criterias: 37,99 ± 12,6 μmol/l in the presence of 2 and 28,3 ± 9,6 μmol/l in the presence of 3 criteria (p<0,05). NOx levels correlated with the amount MS components (r=-0,38, p<0,05). Hypertensives with high leptin levels had lower NOx concentration (29 ± 12,2 μmol/l), compared to hypertensives with normal leptin levels (34,7±10,5 μmol/l) (p<0,05). Conclusion: In essential hypertension NOx metabolism differs in relation to metabolic status. Hypertension per se and hyperglycemia increase NOx levels, whereas MS and its essential signsas visceral obesity and high plasma leptin level decrease NOx levels.

Download Full-text

Blood levels of stable nitric oxide metabolites in metabolic syndrome and diabetes mellitus

Diabetes Mellitus ◽

10.14341/2072-0351-5457 ◽

2009 ◽

Vol 12 (3) ◽

pp. 71-74 ◽

Cited By ~ 1

Author(s):

Zulaykho Muralimzhanovna Shamansurova

Keyword(s):

Nitric Oxide ◽

Diabetes Mellitus ◽

Metabolic Syndrome ◽

Resistance Index ◽

Diagnostic Value ◽

Blood Levels ◽

Postprandial Glycemia ◽

Nitric Oxide Metabolites ◽

Lipid Spectrum

Aim. To measure stable metabolites of nitric oxide (SMNO), i.e. nitrites and nitrates, and compare the results with other biochemical characteristicsof blood in patients with type 1 and 2 diabetes mellitus (DM1 and DM2) or metabolic syndrome (MS). Materials and methods. The following parameters were measured in 61 patients with DM, 12 with obesity, 8 with impaired glucose tolerance (IGT),and 12 healthy subjects: blood glucose level (fasting and 2 hr postprandially), HbA1c, insulin, C-peptide, SMNO, lipid spectrum, erythrocyte sialidaseactivity (ESA), and insulin resistance index (HOMA). Results. Postprandial glycemia was elevated in DM1, DM2, and IGT patients, HOMA in those with DM2 and IGT, ESA in all DM and MS patients.SMNO level was reduced in all groups especially in patients with DM and diabetic nephropathy. It negatively correlated with total cholesterol, TG,LDL, and ESA. Conclusion. Blood SMNO level as an indicator of endothelial dysfunction is of high diagnostic value starting from the early stages of impaired carbohydratemetabolism.

Download Full-text

Evaluation of nitric oxide metabolites in a group of subjects with metabolic syndrome

Diabetes & Metabolic Syndrome Clinical Research & Reviews ◽

10.1016/j.dsx.2012.09.012 ◽

2012 ◽

Vol 6 (3) ◽

pp. 132-135 ◽

Cited By ~ 11

Author(s):

Gregorio Caimi ◽

Eugenia Hopps ◽

Maria Montana ◽

Davide Noto ◽

Baldassare Canino ◽

...

Keyword(s):

Nitric Oxide ◽

Metabolic Syndrome ◽

Nitric Oxide Metabolites

Download Full-text

Influence of metabolic syndrome components on the level of nitric oxide stable metabolites in patients with essential hypertension

Systemic Hypertension ◽

10.26442/sg29075 ◽

2015 ◽

Vol 12 (2) ◽

pp. 57-61

Author(s):

V I Podzolkov ◽

A E Bragina ◽

G I Bragina ◽

N A Murashko

Keyword(s):

Nitric Oxide ◽

Metabolic Syndrome ◽

Essential Hypertension ◽

Healthy Volunteers ◽

The Metabolic Syndrome ◽

Nitric Oxide Metabolites ◽

Metabolic Syndrome Components

Objective. To investigate levels of the stable nitric oxide metabolites (NOx) in relation to different components of the metabolic syndrome (MS) in essential hypertension (EH).Methods. We examined 124 untreated patients with EH and 25 healthy volunteers with comparable age.Results. NOx levels were significantly higher in hypertensives (43.18±21, mol/l) then in controls (28.3±9.6 mol/l); p

Download Full-text

The effect of glyproline peptides on levels of nitric oxide metabolites and tissue plasminogen activator activity in healthy rats and rats with metabolic syndrome

ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» ◽

10.25557/0031-2991.2020.04.88-94 ◽

2020 ◽

pp. 88-94

Author(s):

Т.Ю. Оберган ◽

М.Е. Григорьева ◽

Л.А. Ляпина ◽

Т.А. Шубина ◽

Н.Ф. Мясоедов ◽

...

Keyword(s):

Nitric Oxide ◽

Metabolic Syndrome ◽

Endothelial Function ◽

Plasminogen Activator ◽

Tissue Plasminogen Activator ◽

Tissue Plasminogen ◽

Male Wistar Rats ◽

Nitric Oxide Metabolites ◽

Nitrate And Nitrite ◽

Academy Of Sciences

Введение. Короткие регуляторные пролинсодержащие пептиды могут оказывать противосвертывающие эффекты в организме и проявлять защитное действие при тромбозах. Цель исследования - выявление косвенных эффектов пептидов глипролинового ряда Pro-Gly-Pro (PGP) и Arg-Glu-Arg-Pro-Gly-Pro (RERPGP) на функцию эндотелия сосудов и состояние системы фибринолиза в норме и при нарушении липидного обмена. Методика. Пептиды были синтезированы в институте молекулярной генетики РАН. В экспериментах использовано 60 лабораторных белых крыс-самцов линии Wistar. Проведено 2 серии экспериментов - на здоровых крысах и животных с экспериментально воспроизведенным метаболическим синдромом (МС). Пептиды вводили интраназально в течение 7 сут через каждые 24 ч (100 мкг/кг) ежедневно. Анализ крови осуществляли через 20 и 168 ч после завершающего введения пептидов. Определяли уровни метаболитов оксида азота (NO) и активности тканевого активатора плазминогена (ТАП). Результаты. Выявлены различия в действии PGP и RERPGP на исследуемые параметры у здоровых животных. В плазме крови крыс через 20 ч после семикратного введения пептида PGP установлено значительное повышение активности ТАП и метаболитов NO, которое сохранялось на протяжении 168 ч эксперимента, в то время как под влиянием RERPGP отмечалось повышение только уровня нитратов и нитритов через 168 ч после его применения. Пептид PGP также оказывал выраженные эффекты на функцию эндотелия организма и при развитии МС. Активность ТАП значительно и статистически значимо увеличивалась через 20 ч после семикратного введения пептида, эти изменения наблюдались также спустя 168 ч после применения PGP. Эти величины практически соответствовали значениям ТАП у здоровых крыс. Уровень метаболитов NО также значимо повышался при воздействии PGP на фоне МС. Сделано предположение о возможных механизмах действия пептидов на сосудистый эндотелий. Заключение. Пептиды глипролинового ряда оказывали стимулирующее влияние на функцию эндотелия в организме как в норме, так и при патологии, повышая активность тканевого активатора плазминогена и концентрацию метаболитов оксида азота. Short regulatory proline-containing peptides can exert an anticoagulation effect and be protective in thrombosis. The aim of this study was to identify indirect effects of glyproline peptides Pro-Gly-Pro (PGP) и Arg-Glu-Arg-Pro-Gly-Pro (RERPGP) on vascular endothelial function and the fibrinolytic system in normal and impaired lipid metabolism. Methods. Peptides were synthesized at the Institute of Molecular Genetics, Russian Academy of Sciences. Experiments were performed on 60 male Wistar rats divided into healthy animals and animals with experimental metabolic syndrome (MS). Peptides (100 μg/kg) were administered intranasally, once a day for 7 days. Blood tests were performed 20 h and 168 h after the last administration of the peptides. Concentrations of nitric oxide (NO) metabolites (sum plasma concentration of nitrate and nitrite) and the activity of tissue plasminogen activator (TAP) were measured. Results. The effects of PGP and RERPGP on the endothelial function in healthy animals were different. Significant increases in both TAP activity and NO metabolite concentration were found in plasma 20 h after 7 PGP administrations, which persisted throughout 168 h of the experiment. Only an increase in nitrate/nitrite was observed at 168 h after the RERPGP administration. PGP also exerted pronounced effects on the endothelial function, including in MS. TAP activity was significantly increased at 20 h after 7 administrations of the peptide, and this effect remained at 168 h after the PGP administration. These values were practically similar to the TAP values in healthy rats. Concentrations of NO metabolites were also significantly increased after the PGP exposure of MS rats. Possible mechanisms for the peptide activation of vascular endothelium are discussed. Conclusion. Glyproline peptides had a stimulatory effect on the endothelial function both in normal and pathological conditions by increasing the TAP activity and the concentration of NO metabolites.

Download Full-text